Cellular and Humoral Responses to Recombinant and Inactivated SARS-CoV-2 Vaccines in CKD Patients: An Observational Study.

Siliang ZhangJiaoxia HeBin TangQin ZhouYudong HuYuan YuJianwei ChenYi LiuChunmeng LiHong RenXiaohui Liao

Published in: Journal of clinical medicine (2023)

The recombinant and inactivated SARS-CoV-2 vaccine was well-tolerated and showed a good response in the CKD cohort. Our study also revealed differences in MBC subtypes after SARS-CoV-2 vaccination between CKD patients and healthy controls.

Keyphrases

sars cov
end stage renal disease
chronic kidney disease
ejection fraction
newly diagnosed
respiratory syndrome coronavirus
peritoneal dialysis
immune response
prognostic factors